Docoh
Loading...

PRPO Precipio

Filed: 14 Nov 06, 7:00pm
                                                                    Exhibit 99.1

                  TRANSGENOMIC APPOINTS CHIEF FINANCIAL OFFICER

    OMAHA, Neb., Nov. 14 /PRNewswire-FirstCall/ -- Transgenomic, Inc.
(Nasdaq: TBIO) today announced that Debra A. Schneider has been named as Vice
President and Chief Financial Officer effective December 4, 2006.  Ms.
Schneider will report to Craig Tuttle, Transgenomic's President and Chief
Executive Officer, and will oversee finance, accounting, investor relations,
and administration.

    Ms. Schneider has spent the last seventeen years at First Data Corporation
in a number of roles including finance planning, accounting and Chief Financial
Officer for various business units. First Data Corporation is a provider of
processing and related services to institutions issuing credit and debit cards.
Most recently she served as Senior Vice President of Finance. Prior to her
tenure at First Data Corporation, she worked as Controller at Creative
Financing, Inc. and as an accountant with KPMG.

    Ms. Schneider holds a B.S. in Business Administration, Accounting from the
University of Nebraska-Omaha and is a Certified Public Accountant.

    In making the announcement, Transgenomic's President and Chief Executive
Officer, Craig Tuttle, stated, "We are very excited to have Debra joining our
team at Transgenomic. She has a tremendous background and experience base in
both GAAP accounting and SEC reporting and a history of strong senior level
leadership. Her skills in cost modeling and resource allocation will prove
invaluable as we move towards profitable operations."

    About Transgenomic

    Transgenomic is a global biotechnology company that provides unique systems,
products, discovery and laboratory testing services to the academic and medical
research, clinical and pharmaceutical markets for automated high sensitivity
genetic variation and mutation analysis in the fields of pharmacogenomics and
personalized medicine. This is accomplished through their offerings of Wave(TM)
DHPLC systems, reagents, consumables and assay kits, automated cytogenetics
systems and Transgenomic Discovery and CLIA Lab Services. To date there have
been over 1,200 Wave systems installed in over 600 customer sites in over 35
countries and approximately 1,500 publications utilizing Transgenomic products
or services. Transgenomic Discovery and Lab Services utilize their technology
and expertise to provide a menu of mutation scanning tests for over 700
cancer-associated genes and more than 60 validated diagnostic tests to meet the
needs of pharmaceutical and biotech companies, research and clinical
laboratories, physicians and patients. For more information about the innovative
systems, products and services offered by Transgenomic, please visit:
www.transgenomic.com.

    Transgenomic Cautionary Statements

    Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements include, but
are not limited to, those with respect to management's current views and
estimates of future economic circumstances, industry conditions, company
performance and financial results, including the ability of the Company to grow
its involvement in the diagnostic products and services markets. The known
risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's reports to the
Securities and Exchange Commission. Any change in such factors, risks and
uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements. Accordingly, the company
claims the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995 with respect
to all statements contained in this press release. All information in this press
release is as of the date of the release and Transgenomic does not undertake any
duty to update this information, including any forward-looking statements,
unless required by law.

SOURCE  Transgenomic, Inc.
    -0-                             11/14/2006
    /CONTACT:  Craig J. Tuttle of Transgenomic, Inc., +1-402-452-5400/
    /Web site:  http://www.transgenomic.com /